Research And Development
Health
Manufacturing

ACADIA Pharmaceuticals

$26.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.70 (-2.60%) Today
-$0.22 (-0.84%) After Hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, ETFs, and crypto commission-free!

About

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. Read More The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Employees
430
Headquarters
San Diego, California
Founded
1993
Market Cap
3.77B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.69M
High Today
$27.09
Low Today
$25.95
Open Price
$26.97
Volume
421.79K
52 Week High
$28.12
52 Week Low
$12.77

Collections

Research And Development
Health
Manufacturing
Pharmaceutical
Technology
Medical
Biotechnology

News

MarketBeatMar 17

Stock Price, News, & Analysis for ACADIA Pharmaceuticals

News stories about ACAD stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 1.0...

71
Simply Wall StMar 14

Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Potentially Underrated?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case of ACAD, it is a company with strong financial health as well as a excellent future outlook. Below, I’ve touched on some key aspects you should know on a high level. If you’re interested in understanding beyond my broad commentary, read the full report on ACADIA Pharmaceuticals here. Flawless balance sheet ...

89
Yahoo FinanceMar 5

Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT

Q4 2018 ACADIA Pharmaceuticals Inc Earnings Call SAN DIEGO Mar 6, 2019 (Thomson StreetEvents) -- Edited Transcript of ACADIA Pharmaceuticals Inc earnings conference call or presentation Tuesday, February 26, 2019 at 10:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Elena Ridloff ACADIA Pharmaceuticals Inc. - Interim CFO & Se...

43

Earnings

-$0.72
-$0.63
-$0.53
-$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.